诺华IgA肾病新药在中国申报上市!国内入局者包括云顶新耀、荣昌生物、恒瑞医药等

中国制药网
27 Nov 2024

IgA肾病是一种常见的原发性肾小球疾病,对药物需求巨大。有数据预测,全球IgA肾病治疗药物市场预计将快速增长,中国市场的增长尤为显著,预计将从2020年的0.37亿美元增至2025年的1.09亿美元,复合年增长率达24.6%。据悉,11 月 26 日,CDE 网站显示,诺华的盐酸阿曲生坦片在国内提交上市申请,适应症为用于降低有疾病进展风险的原发性免疫球蛋白 A 肾病(IgAN)成人患者的蛋白尿,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10